Scientists Discover How Key CFTR Channel Blocker Works Through Two Distinct Mechanisms

This breakthrough research reveals how GlyH-101, a crucial drug for studying and potentially treating cystic fibrosis, actually works at the molecular level. Understanding these mechanisms could lead to more effective treatments for this life-threatening genetic disease.

Scientists studied CFTR chloride channels, which are defective in cystic fibrosis patients. They used advanced electrophysiology techniques to examine how GlyH-101 blocks these channels, recording both whole-cell and single-channel activity under various conditions.

The team discovered GlyH-101 operates through two distinct blocking mechanisms. First, it can plug channels from the outside in a voltage-dependent manner, creating rapid blockade. Second, because it's fat-soluble, it crosses cell membranes and blocks channels from inside through a slower, voltage-independent process involving two sequential steps.

To prove this dual mechanism, researchers created GlyH-101-1, a water-soluble version that cannot cross membranes. This modified compound only blocked channels from the inside, confirming their hypothesis about the original drug's dual action.

For longevity and health, this research advances our understanding of ion channel regulation, which affects multiple bodily functions including lung health, digestion, and cellular hydration. Better CFTR modulators could improve quality of life and lifespan for cystic fibrosis patients, while the research methodology could accelerate development of treatments for other ion channel disorders affecting aging and health.